Projekt: Spremljanje varnosti cepiv proti COVID-19

Akronim projekta: CoVaST

Trajanje projekta: 2021-2026

Glavni koordinator projekta: izr. prof. dr. Miloslav Klugar, Czech National Centre for Evidence-Based Healthcare and Knowledge Translation (Cochrane Czech Republic, Czech EBHC: JBI Centre of Excellence, Masaryk University GRADE Centre), Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University Masaryk University, Brno, Czech Republic

Slovenski koordinator projekta: prof. dr. Janja Marc, Univerza v Ljubljani, Fakulteta za farmacijo, Ljubljana, Slovenija

Sodelujoči slovenski raziskovalci: izr. prof. dr. Barbara Ostanek (FFA, UL), asist. dr. Irena Prodan Žitnik (FFA UL), dr. Tatjana Mrvič, dr. med. (UKC, Ljubljana)

Povzetek projekta:
Cepiva proti COVID-19 predstavljajo najbolj učinkovit ukrep za obvladovanje pandemije, zato je čim višji delež cepljenih glavna prioriteta zdravstvenih sistemov povsod po svetu. Raziskave kažejo, da imajo neželeni učinki cepiv pomembno vlogo pri odločitvah posameznikov glede cepljenja in da ozaveščanje javnosti o učinkovitosti cepiv in njihovih neželenih učinkih, pomembno prispevata k precepljenosti.
Namen študije »Spremljanje varnosti cepiv proti COVID-19 (CoVaST)« je globalno spremljanje varnosti in učinkovitosti cepiv proti COVID-19 v štirih ciljnih populacijah – zdravstveni delavci, pedagoški delavci, starostniki (starejši od 65 let) in mladostniki (mlajši od 18 let). Raziskava bo potekala v več fazah, podatke pa bomo pridobili z uporabo validiranih vprašalnikov za samooceno. V prvi fazi bomo preverjali pojavnost kratkoročnih lokalnih in sistemskih neželenih učinkov po cepljenju proti COVID-19. V drugi fazi bomo raziskovali neželene učinke po obnovitvenih odmerkih, v tretji fazi, ki bo trajala 5 let, pa bomo preučevali dolgoročno varnost in učinkovitost cepiv. Raziskavo je registrirala U.S. National Library of Medicine (NLM), pod številko NCT04834869. Več informacij o razskavi pa je dostopnih v članku na povezavi 10.3390/ijerph18157859
CoVaST je prva neodvisna multinacionalna študija, ki bo aktivno spremljala kratkoročne in dolgoročne neželene učinke cepiv proti COVID-19 ter učinkovitost cepljenja.

Project summary:
COVID-19 vaccines are the foremost asset to overcome the ongoing pandemic; therefore, mass vaccination has become a high priority for world's governments. Suides have demonstrated that vaccine-related side effects have a determinant
role in the public decision regarding vaccination and raising public awareness of vaccines' effectiveness and honesty regarding their side effects are vital strategies to improve vaccine uptake.
The aim of the project is to actively monitor the safety and effectiveness of COVID-19 vaccines globally in four target population groups: healthcare workers, teachers and academics, senior adults (≥ 65 years) and minors (≤18 years). This multicountry, three-phase study will include a cross-sectional survey to test for the short-term side effects of COVID-19 vaccines in the firts phase. In the second phase, we will monitor the booster doses' side effects, while in the third phase, the long-term safety and effectiveness will be investigated. A validated, self-administered questionnaire will be used to collect data from the target population. The study protocol has been registered at ClinicalTrials.gov, with the identifier NCT04834869 and additional information is available 10.3390/ijerph18157859.

CoVaST is the first independent study aiming to monitor the side effects of COVID-19 vaccines following booster doses, and the long-term safety and effectiveness of vaccines.